Combination of intravitreal rtPA, gas and ranibizumab for extensive subfoveal haemorrhages secondary to neovascular age-related macular degeneration;Kombinierte intravitreale Injektion von rTPA, Gas und Ranibizumab zur Behandlung großflächiger subfovealer Blutungen bei neovaskulärer altersbedingter Makuladegeneration

Klinische Monatsblatter fur Augenheilkunde

Volumn 227, Issue 3, 2010, Pages 221-225

  Matt, G ^a   Sacu, S ^a   Stifter, E ^a   Prunte C ^a   Schmidt Erfurth, U ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

Author keywords

Gas; Neovascular age related macular degeneration; Ranibizumab; Recombinant tissue plasminogen activator; Subfoveal haemorrhage

Indexed keywords

ALTEPLASE; DEXAMETHASONE; GENTAMICIN; RANIBIZUMAB; SULFUR HEXAFLUORIDE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; EYE EXAMINATION; FLUORESCENCE ANGIOGRAPHY; HUMAN; INTRAOCULAR PRESSURE; OPTICAL COHERENCE TOMOGRAPHY; OUTCOME ASSESSMENT; RETINA HEMORRHAGE; RETINA MACULA AGE RELATED DEGENERATION; RETROSPECTIVE STUDY; SIDE EFFECT; VISUAL ACUITY;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; DRUG COMBINATIONS; EYE HEMORRHAGE; FEMALE; GASES; GLAUCOMA, NEOVASCULAR; HUMANS; MACULAR DEGENERATION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; TISSUE PLASMINOGEN ACTIVATOR; TREATMENT OUTCOME; VITREOUS BODY;

EID: 77949667955     PISSN: 00232165     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0028-1109750     Document Type: Article

References (22)

1. Avery R L., Fekrat S, Hawkins B S. et al. Natural history of subfoveal subretinal hemorrhage in age-related macular degeneration. Retina 1996 16 (3) 183-189
2. rd M B. et al. Fibrinolytic-assisted removal of experimental subretinal hemorrhage within seven days reduces outer retinal degeneration. Ophthalmology 1994 101 (4) 672-681
3. Bennett S R., Folk J C., Blodi C F. et al. Factors prognostic of visual outcome in patients with subretinal hemorrhage. Am J Ophthalmol 1990 109 (1) 33-37
4. Berrocal M H., Lewis M L., Flynn H W. Variations in the clinical course of submacular hemorrhage. Am J Ophthalmol 1996 122 (4) 486-493
5. Brown D M., Kaiser P K., Michels M Jr et al. Ranibizumab versus verteporfin for neovascular age-related macular degeneration. N Engl J Med 2006 355 (14) 1432-1444
6. Chen C Y., Hooper C, Chiu D et al. Management of submacular hemorrhage with intravitreal injection of tissue plasminogen activator and expansile gas. Retina 2007 27 (3) 321-328
7. Daneshvar H, Kertes P J., Leonard B C. et al. Management of submacular hemorrhage with intravitreal sulfur hexafluoride: a pilot study. Can J Ophthalmol 1999 34 (7) 385-388
8. Glatt H, Machemer R. Experimental subretinal hemorrhage in rabbits. Am J Ophthalmol 1982 94 (6) 762-773
9. Hassan A S., Johnson M W., Schneiderman T E. et al. Management of submacular hemorrhage with intravitreous tissue plasminogen activator injection and pneumatic displacement. Ophthalmology 1999 106 (10) 1900-1906, discussion 6 7
10. Hattenbach L O., Klais C, Koch F H. et al. Intravitreous injection of tissue plasminogen activator and gas in the treatment of submacular hemorrhage under various conditions. Ophthalmology 2001 108 (8) 1485-1492
11. Heier J S., Antoszyk A N., Pavan P R. et al. Ranibizumab for treatment of neovascular age-related macular degeneration: a phase I/II multicenter, controlled, multidose study. Ophthalmology 2006 113 (4) 633 e1-e4
12. Hesse L, Schmidt J, Kroll P. Management of acute submacular hemorrhage using recombinant tissue plasminogen activator and gas. Graefes Arch Clin Exp Ophthalmol 1999 237 (4) 273-277
13. Ibanez H E., Williams D F., Thomas M A. et al. Surgical management of submacular hemorrhage. A series of 47 consecutive cases. Arch Ophthalmol 1995 113 (1) 62-69
14. Meier P, Zeumer C, Jochmann C et al. Management of submacular hemorrhage by tissue plasminogen activator and SF(6) gas injection. Ophthalmologe 1999 96 (10) 643-647
15. Meyer C H., Scholl H P., Eter N et al. Combined treatment of acute subretinal haemorrhages with intravitreal recombined tissue plasminogen activator, expansile gas and bevacizumab: a retrospective pilot study. Acta Ophthalmol 2008 86 (5) 490-494
16. Morse L S., Benner J D., Hjelmeland L M. et al. Fibrinolysis of experimental subretinal haemorrhage without removal using tissue plasminogen activator. Br J Ophthalmol 1996 80 (7) 658-662
17. Ohji M, Saito Y, Hayashi A et al. Pneumatic displacement of subretinal hemorrhage without tissue plasminogen activator. Arch Ophthalmol 1998 116 (10) 1326-1332
18. Rosenfeld P J., Brown D M., Heier J S. et al. Ranibizumab for neovascular age-related macular degeneration. N Engl J Med 2006 355 (14) 1419-1431
19. Rosenfeld P J., Rich R M., Lalwani G A. Ranibizumab: Phase III clinical trial results. Ophthalmol Clin North Am 2006 19 (3) 361-372
20. Sacu S, Stifter E, Vecsei-Marlovits P V. et al. Management of extensive subfoveal haemorrhage secondary to neovascular age-related macular degeneration. Eye 2009 23 (6) 1404-1410
21. Schulze S D., Hesse L. Tissue plasminogen activator plus gas injection in patients with subretinal hemorrhage caused by age-related macular degeneration: predictive variables for visual outcome. Graefes Arch Clin Exp Ophthalmol 2002 240 (9) 717-720
22. Toth C A., Morse L S., Hjelmeland L M. et al. Fibrin directs early retinal damage after experimental subretinal hemorrhage. Arch Ophthalmol 1991 109 (5) 723-729